Loading...
Pfizer's RSV vaccine is trailing behind GSK's in a head-to-head competition. Pfizer reported a net loss of $2.38 billion in Q3, with revenue down 42% compared to last year. The company's results missed expectations due to declining sales of its Covid-19 shot and Paxlovid pill. Pfizer took a $4.7 billion write-off in Q3 due to excess inventory of Paxlovid. The slump in demand for Covid products has caused Pfizer to swing to a quarterly loss.
Pfizer revenue down 42% from last year after decreased demand for Covid vaccines https://t.co/keX5z4nJUx https://t.co/keX5z4nJUx
Pfizer reports loss as Covid-19 revenues shrink https://t.co/BGGKlkuJSN
Pfizer Takes a Big Hit Due to Shrinking Demand for Covid Vaccines Pfizer reported an adjusted loss for the third quarter on Tuesday, as the pharmaceutical company is struggling to market its Covid antiviral treatment Paxlovid and the Covid vaccine "boosters." The Big Pharma… https://t.co/GvrJDbl7s5 https://t.co/ngSO28Ze9U
$PFE (-0.7% pre) Pfizer Earnings Dragged Down by Weak Demand for Covid Products https://t.co/cwFEHE2QhI
Pfizer swings to quarterly loss as COVID product demand slump sparks charges https://t.co/32mApC0aCW https://t.co/SveZ9kA4sp
$AMGN (-0.3% pre) Amgen Boosts Revenue Guidance. But the Stock Trades Lower. https://t.co/j7Jlx2jQ9P
JUST IN - Pfizer reports a net loss of $2.38 billion in Q3, revenue down 42% compared to last year — CNBC
Yikes: Pfizer took a **$4.7 billion write-off** in the third quarter due to excess inventory of COVID treatment Paxlovid after the U.S. government returned 7.9 million emergency doses to the company.
Amgen raises its full-year revenue guidance after closing the purchase of rare-disease drugmaker Horizon Therapeutics earlier this month https://t.co/HKkAASXXJ9
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs https://t.co/3JmhTrFOX8
Pfizer's results missed expectations for the quarter as sales of its Covid-19 shot and Paxlovid pill continued to tumble https://t.co/n2MJZFHKlq
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales https://t.co/cSdL4O83Dx
PFIZER RSV VACCINE LAGS GSK’S AS HEAD-TO-HEAD COMPETITION UNDERWAY (Reuters) Pfizer finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. https://t.co/lQQZZNK7nF
The drugmaker is set to disclose its results. Investors are focused on Covid-19 drugs despite a recent flurry of product launches. https://t.co/NHoEtG6w3O
$PFE $GSK Pfizer RSV vaccine lags GSK’s as head-to-head competition underway - Reuters https://t.co/aVhOoNe71E